These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


93 related items for PubMed ID: 2236509

  • 41. Inactivation and repair of double-stranded DNA damaged by the aziridinyl nitroimidazole RSU 1069.
    Lafleur MV, Westmijze EJ, Visser OJ, Wagenaar N, Soetekouw R, Loman H, Retel J.
    Chem Biol Interact; 1992 Mar; 82(1):55-71. PubMed ID: 1532139
    [Abstract] [Full Text] [Related]

  • 42. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
    Henry JM, Isaacs JT.
    J Urol; 1989 Jul; 142(1):165-70. PubMed ID: 2733098
    [Abstract] [Full Text] [Related]

  • 43. Cytotoxicity of dual function nitrofurans in rodent and human tumor cells.
    Siemann DW.
    Int J Radiat Oncol Biol Phys; 1992 Jul; 22(4):697-700. PubMed ID: 1544840
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Studies on the toxicity of RSU-1069.
    Whitmore GF, Gulyas S.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1219-22. PubMed ID: 3755716
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Oncogenic transformations in vitro produced by misonidazole.
    Miller RC, Hall EJ.
    Cancer Clin Trials; 1980 Jul; 3(1):85-90. PubMed ID: 7389040
    [Abstract] [Full Text] [Related]

  • 53. In vitro transformation by bromodeoxyuridine and X irradiation in C3H 10T1/2 cells.
    Raaphorst GP, Azzam EI, Borsa J, Sargent MD.
    Radiat Res; 1985 Feb; 101(2):279-91. PubMed ID: 3975357
    [Abstract] [Full Text] [Related]

  • 54. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 55. The nitroimidazoles as radiosensitizers and cytotoxic agents.
    Hall EJ, Miller R, Astro M, Rini F.
    Br J Cancer Suppl; 1978 Jun; 3():120-3. PubMed ID: 277211
    [Abstract] [Full Text] [Related]

  • 56. Neurotoxicity of radiation sensitizers in the mouse.
    Clarke C, Dawson KB, Sheldon PW, Ahmed I.
    Int J Radiat Oncol Biol Phys; 1982 Jun; 8(3-4):787-9. PubMed ID: 7107415
    [Abstract] [Full Text] [Related]

  • 57. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
    Bremner JC.
    Cancer Metastasis Rev; 1993 Jun; 12(2):177-93. PubMed ID: 8375020
    [Abstract] [Full Text] [Related]

  • 58. Interaction of RSU 1069 and 1137 with DNA in vitro. Biological implications and mechanistic aspects.
    Lafleur MV, Westmijze EJ, Visser OJ, Wagenaar N, Soetekouw R, Loman H, Retèl J.
    Biochem Pharmacol; 1991 Jun 01; 41(11):1649-55. PubMed ID: 1828345
    [Abstract] [Full Text] [Related]

  • 59. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
    Chaplin DJ, Acker B.
    Int J Radiat Oncol Biol Phys; 1987 Apr 01; 13(4):579-85. PubMed ID: 3558048
    [Abstract] [Full Text] [Related]

  • 60. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Chaplin DJ.
    Radiat Res; 1988 Aug 01; 115(2):292-302. PubMed ID: 3406369
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 5.